Most Clicked StoriesMore >


Eli Lilly Alzheimer's drug fails clinical trial

FDLI SmartBrief | Nov 28, 2016

Eli Lilly and Co. halted a large-scale trial of the drug solanezumab after it failed to achieve significant results in slowing cognitive decline in patients with mild Alzheimer's symptoms. Solanezumab is an antibody intended to reduce the buildup of amyloid plaques in the brain. The Wall Street Journal (tiered subscription model) (11/23) The New York Times (free-article access for SmartBrief readers) (11/23)


FDA warns against dietary supplement containing undeclared drugs

FDLI SmartBrief | Dec 01, 2016

FDA approves clinical trials of Alzheimer's/schizophrenia drug

FDLI SmartBrief | Nov 29, 2016

21st Century Cures Act clears House

FDLI SmartBrief | Dec 01, 2016

Juno's leukemia drug on hold after patient deaths

FDLI SmartBrief | Nov 28, 2016

Merck's Keytruda given FDA priority review for lung cancer

FDLI SmartBrief | Nov 29, 2016

Indian drugmakers blacklisted by Vietnam

FDLI SmartBrief | Nov 28, 2016

Ariad's treatment for rare leukemias receives FDA approval

FDLI SmartBrief | Nov 30, 2016

Study shows positive results for Neuronix's Alzheimer's treatment system

FDLI SmartBrief | Dec 01, 2016

Gilead now marketing Truvada for HIV prevention

FDLI SmartBrief | Dec 01, 2016


Find FDLI SmartBrief Issues by Date:



FDLI News More >


2017 FDLI Annual Conference, May 4-5, Washington, D.C.

FDLI SmartBrief | Dec 02, 2016

Tobacco and Nicotine Delivery: Regulation and Compliance, 2nd Ed.

FDLI SmartBrief | Dec 02, 2016

Two weeks away! The Yates Memo: A Lawyer's Professional Responsibility webinar, Dec. 14, 2-3:30 p.m. ET

FDLI SmartBrief | Dec 01, 2016

Deadline tomorrow, Dec. 2! Call for proposals: 2017 FDLI Annual Conference, May 4-5, Washington, D.C.

FDLI SmartBrief | Dec 01, 2016

One week away! Enforcement, Litigation, and Compliance Conference, Dec. 7-8, Washington, D.C.

FDLI SmartBrief | Nov 30, 2016




Sign up for FDLI SmartBrief



Designed specifically for professionals involved in the food and drug law community, FDLI SmartBrief is a FREE daily e-mail newsletter. It provides the latest need-to-know news and industry information that maximizes your time, giving you an edge over your competition. Learn more

Recent Poll view more polls


What affect do you think this year's media focus on imported drug, food and medical device product safety will have in 2010?

Chart.